Repurposing doxepin as an antitumor agent: Suppression of cell migration, invasion and survival in non‑small cell lung cancer through ERK/NF‑κB downregulation

Non‑small cell lung cancer (NSCLC) remains a global health challenge due to high metastatic potential and resistance to conventional apoptosis. Doxepin, a tricyclic antidepressant, has shown emerging antitumor potential, yet its efficacy and underlying mechanisms in NSCLC remain poorly understood. The effects of doxepin were evaluated on NSCLC cell lines (A549 and CL1‑5‑F4). Cell viability and apoptosis were assessed using an MTT assay and annexin V/PI flow cytometry. Migratory and invasive capacities were measured using Transwell assays. Western blotting was employed to investigate the ERK/NF‑κB signaling axis and associated regulatory proteins. Doxepin notably suppressed cell viability and induced apoptosis through both extrinsic (caspase‑8) and intrinsic (caspase‑9) pathways in a dose‑ and time‑dependent manner. Furthermore, doxepin treatment markedly inhibited cell migration and invasion. Mechanistically, doxepin inactivated the ERK/NF‑κB axis, leading to the downregulation of anti‑apoptotic (cellular FLICE‑like inhibitory protein, myeloid cell leukemia 1 and X‑linked inhibitor of apoptosis protein) and pro‑metastatic (vascular endothelial growth factor A and matrix metalloproteinase‑9) factors. These findings demonstrate that doxepin effectively inhibits NSCLC progression by promoting apoptosis and suppressing metastasis, suggesting its potential as a repositioned therapeutic agent for lung cancer treatment.

Authors

Institutions

Publication Details

Journal
Oncology Letters
Published
2026-11-20
DOI
https://doi.org/10.3892/ol.2026.15960
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Repurposing doxepin as an antitumor agent: Suppression of cell migration, invasion and survival in non‑small cell lung cancer through ERK/NF‑κB downregulation

Dai-Cheng Dong, Shih-Chieh Chang, Fei-Ting Hsu, Jiun-I Lai et al.
1 links
Oncology Letters
Lung Cancer Treatments and Mutations
article

Repurposing doxepin as an antitumor agent: Suppression of cell migration, invasion and survival in non‑small cell lung cancer through ERK/NF‑κB downregulation

Dai-Cheng Dong, Shih-Chieh Chang, Fei-Ting Hsu, Jiun-I Lai, Yi-Jen Fang, Chiung-Yu Chen
article en

Abstract

Non‑small cell lung cancer (NSCLC) remains a global health challenge due to high metastatic potential and resistance to conventional apoptosis. Doxepin, a tricyclic antidepressant, has shown emerging antitumor potential, yet its efficacy and underlying mechanisms in NSCLC remain poorly understood. The effects of doxepin were evaluated on NSCLC cell lines (A549 and CL1‑5‑F4). Cell viability and apoptosis were assessed using an MTT assay and annexin V/PI flow cytometry. Migratory and invasive capacities were measured using Transwell assays. Western blotting was employed to investigate the ERK/NF‑κB signaling axis and associated regulatory proteins. Doxepin notably suppressed cell viability and induced apoptosis through both extrinsic (caspase‑8) and intrinsic (caspase‑9) pathways in a dose‑ and time‑dependent manner. Furthermore, doxepin treatment markedly inhibited cell migration and invasion. Mechanistically, doxepin inactivated the ERK/NF‑κB axis, leading to the downregulation of anti‑apoptotic (cellular FLICE‑like inhibitory protein, myeloid cell leukemia 1 and X‑linked inhibitor of apoptosis protein) and pro‑metastatic (vascular endothelial growth factor A and matrix metalloproteinase‑9) factors. These findings demonstrate that doxepin effectively inhibits NSCLC progression by promoting apoptosis and suppressing metastasis, suggesting its potential as a repositioned therapeutic agent for lung cancer treatment.

Oncology LettersVol. 33(1)
National Yang Ming Chiao Tung University (TW), National Chung Hsing University (TW), National Central University (TW), National Tsing Hua University (TW), National Yang Ming University Hospital (TW)
Shanghai Educational Development Foundation
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon